酶抑制对单胺氧化酶的测定
Bijo Mathew1, Jong Min Oh2, Della Grace Thomas Parambi3
1Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India. bijomathew@aims.amrita.edu.
Methods in molecular biology (Clifton, N.J.)
|March 1, 2024
概括
本研究详细介绍了准确的连续光谱法测定单胺氧化酶 (MAO) 活性. 这些测试对于开发用于治疗抑郁症,阿尔茨海默氏症等神经疾病的新型MAO抑制剂至关重要.
科学领域:
- 生物化学 生物化学
- 酶学 是一种酶学.
- 神经科学是一个神经科学.
背景情况:
- 单胺氧化酶 (MAO) 存在两个同位体,MAO-A和MAO-B,对于神经递质调节至关重要.
- MAO-A和MAO-B与神经疾病有关,导致需要选择性抑制剂.
- 选择性MAO-A抑制剂正在研究抑郁症,而MAO-B抑制剂正在研究阿尔茨海默氏症和帕金森病.
研究的目的:
- 为量化MAO-A和MAO-B活性提供准确的连续光谱法.
- 为开发新型MAO抑制剂提供基础.
主要方法:
- 连续光谱测定测试使用金胺用于MAO-A和胺用于MAO-B.
- 对MAO-A产品 (4-基) 的光谱测定在316nm,对MAO-B产品 (甲) 的测定在250nm.
- 使用Lineweaver-Burk和二次图表分析抑制动力学,并通过透析评估抑制剂的可逆性.
主要成果:
- 已经建立了可靠的MAO-A和MAO-B活性光谱测试.
- 证明了用于表征抑制剂强度,模式和可逆性的方法.
结论:
- 连续光谱测定为MAO活性确定提供了高准确度.
- 这些方法对于合理设计和开发治疗性MAO抑制剂至关重要.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.连续测试试验 连续测试试验的MAO-A抑制剂.在MAO-B抑制剂中使用MAO-B抑制剂.一种单胺氧化酶 (monoamine oxidase) 的存在帕金森病是帕金森氏症的一种疾病.更多相关视频
10:28A Semi-High-Throughput Adaptation of the NADH-Coupled ATPase Assay for Screening Small Molecule Inhibitors
Published on: August 17, 2019
9.6K
10:24NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases
Published on: June 30, 2019
10.0K
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Enzyme Inhibition
78.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.3K
